Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

That means millions more Americans may get access to Lilly’s new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.

Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.